Yongfeng Zhou

Dr. Yongfeng Zhou


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2021 in Chinese Medicine
Verified
Journal Article
Open access
PDF file
YZYongfeng Zhou
Yongfeng Zhou
JWJunnan Wang
Junnan Wang
DZDingkun Zhang
Dingkun Zhang
JLJiaxin Liu
Jiaxin Liu
QWQinghua Wu
Qinghua Wu
JPJin Pei
Jin Pei
Drug-induced liver injury (DILI) is a common adverse drug reaction (ADR) and a serious threat to health that affects disease treatments. At present, no targeted clinical drugs are available for DILI. Traditional natural medicines have been widely used as health products. Some natural medicines exert specific hepatoprotective effects, with few side effects and significant clinical efficacy. Thus, natural medicines may be a promising direction for DILI treatment. In this review, we summarize the current knowledge, common drugs and mechanisms of DILI, as well as the clinical trials of natural drugs and their bioactive components in anticipation of the future development of potential hepatoprotective drugs.

3 August 2023 in Chinese Medicine
Verified
Journal Article
Open access
PDF file
SQShanbo Qin
Shanbo Qin
PTPeng Tan
Peng Tan
JXJunjie Xie
Junjie Xie
YZYongfeng Zhou
Yongfeng Zhou
JZJunning Zhao
Junning Zhao
Pulmonary fibrosis is a chronic progressive interstitial lung disease caused by a variety of etiologies. The disease can eventually lead to irreversible damage to the lung tissue structure, severely affecting respiratory function and posing a serious threat to human health. Currently, glucocorticoids and immunosuppressants are the main drugs used in the clinical treatment of pulmonary fibrosis, but their efficacy is limited and they can cause serious adverse effects. Traditional Chinese medicines have important research value and potential for clinical application in anti-pulmonary fibrosis. In recent years, more and more scientific researches have been conducted on the use of traditional Chinese medicine to improve or reduce pulmonary fibrosis, and some important breakthroughs have been made. This review paper systematically summarized the research progress of pharmacological mechanism of traditional Chinese medicines and their active compounds in improving or reducing pulmonary fibrosis. We conducted a systematic search in several main scientific databases, including PubMed, Web of Science, and Google Scholar, using keywords such as idiopathic pulmonary fibrosis, pulmonary fibrosis, interstitial pneumonia, natural products, herbal medicine, and therapeutic methods. Ultimately, 252 articles were included and systematically evaluated in this analysis. The anti-fibrotic mechanisms of these traditional Chinese medicine studies can be roughly categorized into 5 main aspects, including inhibition of epithelial-mesenchymal transition, anti-inflammatory and antioxidant effects, improvement of extracellular matrix deposition, mediation of apoptosis and autophagy, and inhibition of endoplasmic reticulum stress. The purpose of this article is to provide pharmaceutical researchers with information on the progress of scientific research on improving or reducing Pulmonary fibrosis with traditional Chinese medicine, and to provide reference for further pharmacological research.

14 November 2021 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
ZBZhaofang Bai
Zhaofang Bai
PLPengyan Li
Pengyan Li
JWJincai Wen
Jincai Wen
YHYanzhong Han
Yanzhong Han
YCYuanyuan Cui
Yuanyuan Cui
XXXiaohe Xiao
Xiaohe Xiao